$123 Million

Mirati Therapeutics

Follow-on Offering

Lead Left Bookrunner, June 2018

Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Mirati’s lead product candidate, Sitravatinib is a spectrum-selective kinase inhibitor being evaluated both in combination with Nivolumab for the treatment of NSCLC and as a single agent in patients with NSCLC and other tumor types who have genetic alterations in CBL.  In addition to Sitravatinib, Mirati is developing a KRAS G12C inhibitor, MRTX849, for the treatment of NSCLC and CRC